CRDF חוב לטווח קצר של החברה Cardiff Oncology Inc.

The daily price chart for Cardiff Oncology, Inc. (CRDF) on the GURU.Markets platform reflects a trend supported by the development of drugs targeting colorectal, lung, and prostate tumors. Success is driven by the disciplined leadership of Mark Erlander, who has established strategic ties with industry behemoths. The current metric stands at 0.00, confirming the company's status as a developer of universal anti-tumor agents without a narrow specialization in a single modality.

This indicator aggregates the total volume of liabilities with a maturity of up to one year. The metric measures the current credit load, determining the business's ability to service loans without compromising operational activities. For Cardiff Oncology, Inc. (CRDF), controlling these payments is critical when financing the development of the PLK1 inhibitor. Reducing the debt load frees up resources for Onvansertib clinical trials. The dynamics of short-term financial liabilities reflect the overall solvency of the biotech.